Share
7 min read
researchEvidence-based

Rapamycin for APOE4 Carriers: 400 Patients, Zero Dementia (Expert Q&A Recap)

We sat down with a doctor who has 300 person-years of rapamycin data. Some of it surprised me.

T
· Reviewed by Dr. Kevin Tran, PharmD

Key takeaways · TL;DR

Dr. Alan Green's clinical cohort of 300-400 APOE4 carriers on rapamycin recorded zero dementia diagnoses over an average 5 years. Dr. Grant Fraser warns that compounded capsules deliver only one-third of the dose, personalized blood-level dosing varies 6x between similar patients, and only coated FDA-approved tablets should be used.

Definition

Blocking the mechanistic target of rapamycin pathway, which triggers autophagy and cellular cleanup linked to longevity and neuroprotection.

The mTOR pathway regulates cell growth, protein synthesis, and nutrient sensing. Chronic activation accelerates aging-related damage, while periodic inhibition via rapamycin triggers autophagy (cellular self-cleaning) and clears damaged proteins including amyloid-beta and tau aggregates relevant to Alzheimer's. Pulsed weekly dosing, rather than continuous daily dosing, appears to provide longevity benefits without the chronic immunosuppression seen in transplant patients on daily doses.

Rapamycin Formulation Quality for APOE4 Carriers

FormulationAbsorptionCostRecommendation
Compounded capsules~33% of stated doseVariableAvoid per Dr. Fraser
Coated FDA-approved tabletsFull dose~$0.65/mg at CVS with GoodRxPreferred
Liquid/sublingualVariableVariableNot preferred without blood-level validation

Hi Phoenix friend,

We just hosted one of the most requested expert Q&As in Phoenix history.

Dr. Grant Fraser. Board certified in anti-aging and regenerative medicine. 29 years as an ER physician. And over 300 person-years of clinical experience managing rapamycin in patients. (More details about Dr. Fraser below)

More than 50% of his patients are APOE4 carriers. He's also one himself.

We spent over an hour going deep on rapamycin for APOE4: dosing, side effects, when to start, what most people get wrong, and some data that stopped me mid-sentence.

The full Q&A is on YouTube (link below). But here are 3 things that stood out to me.

1. 400 APOE4 patients. Five years. Zero dementia diagnoses.

Dr. Alan Green (a pioneer in rapamycin prescribing) had roughly 1,500 patients on rapamycin before he passed. 300 to 400 of them were APOE4 carriers, mostly in their 60s through 80s.

Prime time for cognitive decline.

Not a single one received a dementia diagnosis over an average of five years.

Now, there are caveats. These patients were affluent, educated, and health-conscious (just by the nature of seeking out someone like Dr. Green). Those factors alone lower dementia risk. But zero out of 300 to 400? Dr. Fraser put it simply: "Seems very unlikely that rapamycin had nothing to do with that."

2. Your rapamycin capsules might only absorb a third of the dose.

This one shocked a few of our members.

If you're taking compounded rapamycin capsules, Dr. Fraser says you're likely only absorbing about one-third of the dose. The capsule gets destroyed in your stomach before the drug can do its job.

His recommendation: only use coated, FDA-approved tablets. They're cheaper too. About 65 cents per milligram at CVS with a GoodRx coupon.

Several Phoenix members on the call were taking compounded capsules and had no idea.

3. Same weight. Same age. 6x the dose.

This is why "just take 5mg a week" is a bad protocol.

Dr. Fraser shared that he has two patients. Same weight, same gender, similar age. One needs 3mg to hit target blood levels. The other needs 18mg.

That's a 6x difference.

Without measuring blood levels (he targets 3 ng/mL at 50 hours post-dose), you're either underdosed and wasting money, or overdosed and risking metabolic side effects. Personalization isn't optional here. It's the whole game.

There's a lot more in the full conversation.

We covered when to start based on your genotype (4/4 vs 3/4 vs 4/2), how to time rapamycin around workouts to protect muscle growth, why Brian Johnson stopped (and why Dr. Fraser didn't), a sleep medication that actually lowers beta amyloid levels, and a bunch of live member Q&A.

Who is Dr. Grant Fraser:
Board Certified: American Board of Anti-Aging and Regenerative Medicine, with fellowship modules in Cardiology, Endocrine and Gastroenterology.
Board Certified American Board of Family Medicine.
Fellow of the Australian College of Rural and Remote Medicine with Advanced Specialty Training in Emergency Medicine and Generalist Emergency Medicine Post Fellowship Certification.
Fellow of the Australian College of General Practitioners.
29 years of experience in Emergency Medicine and Rural Generalist Medicine.
Dr. Fraser’s Youtube channel

This is the kind of conversation that happens inside The Phoenix every month.

If you're already a Phoenix member: submit your questions for our next Q&A with Dr. Fraser on lipid management for APOE4 carriers inside the community. You can also vote on future topics and guests you'd like us to bring on.

If you're not a member yet (and you read this far), you're probably a good fit.

The Phoenix is where APOE4 carriers stop guessing and start running structured experiments, tracking what actually works, and getting direct access to experts like Dr. Fraser who understand our genetics.

Talk soon,
Kevin

Most Newsletters? One-way street.
How boring…
This is the Phoenix Community. So let's make it a two-way street.
Got a question? Feedback?
Hit reply. I read every single one.

Discussion

Join the conversation

Your email will never be published. Be respectful and constructive.

FAQ

Frequently asked questions.

Does rapamycin prevent dementia in APOE4 carriers?
The strongest real-world signal comes from Dr. Alan Green's clinical cohort of roughly 1,500 rapamycin patients, 300 to 400 of whom were APOE4 carriers mostly in their 60s through 80s. Over an average follow-up of five years (prime time for cognitive decline), not a single carrier received a dementia diagnosis. While these patients were affluent, educated, and health-conscious (factors that lower baseline dementia risk on their own), Dr. Grant Fraser's take is that zero diagnoses out of 300 to 400 high-risk carriers makes it very unlikely rapamycin played no role. This is observational clinical data, not a randomized trial, so it should be weighed accordingly.
Should APOE4 carriers use compounded rapamycin capsules?
No, according to Dr. Grant Fraser. Compounded rapamycin capsules are destroyed in the stomach before the drug can be absorbed, meaning patients likely receive only about one-third of the stated dose. His recommendation is to use only coated, FDA-approved rapamycin tablets, which are also cheaper at roughly 65 cents per milligram at CVS with a GoodRx coupon. Several Phoenix members on the expert Q&A call were taking compounded capsules and did not know they were being underdosed. If you are currently on a compounded formulation, discuss switching to coated tablets with a physician experienced in rapamycin prescribing.
How do you dose rapamycin correctly for APOE4?
Dosing must be personalized through blood-level testing, not based on fixed weekly amounts. Dr. Grant Fraser shared that he has two patients of the same weight, gender, and similar age where one needs 3 mg weekly and the other needs 18 mg to hit target blood levels, a 6x difference. He targets a blood rapamycin level of 3 ng/mL measured at 50 hours post-dose. Without blood-level monitoring, you are either underdosed and wasting money or overdosed and risking metabolic side effects like glucose intolerance, lipid changes, or mouth ulcers. Personalization is not optional with rapamycin.
When should APOE4 carriers start rapamycin?
Start timing depends on genotype and personal risk factors. Dr. Grant Fraser's general guidance from the Q&A is that APOE4/4 homozygotes may benefit from starting earlier given their elevated Alzheimer's risk, while 3/4 and 2/4 heterozygotes can weigh their other risk factors (family history, metabolic health, cardiovascular status) before starting. Timing rapamycin around workouts also matters, as mTOR inhibition can blunt muscle growth if taken too close to resistance training. Work with a physician experienced in rapamycin prescribing for APOE4 carriers who can personalize both the start decision and the dosing protocol.
What are the side effects of rapamycin for APOE4 carriers?
Rapamycin at longevity doses is generally well tolerated but can cause mouth ulcers (canker sores), temporary lipid elevations (particularly LDL and triglycerides), glucose intolerance, and mild immunosuppression in some patients. The risk profile is dose-dependent, which is why Dr. Grant Fraser emphasizes blood-level monitoring rather than fixed doses. Most side effects resolve with dose adjustment. APOE4 carriers already monitoring ApoB and HOMA-IR should track these closely during the first few months of rapamycin to catch any metabolic shifts early.
Keep reading

Related protocols.